


```

(F I L E ' H O M E '   E N T E R E D   A T   1 2 : 3 1 : 3 3   O N   1 2   J A N   2 0 1 0 )

L1  F I L E ' R E G I S T R '   E N T E R E D   A T   1 2 : 3 1 : 5 1   O N   1 2   J A N   2 0 1 0
      S T R
L2  F I L E ' R E G I S T R '   E N T E R E D   A T   1 2 : 3 2 : 3 8   O N   1 2   J A N   2 0 1 0
L3  6 0   S   L 1
L4  7 1 6 0   S   L 1   F U L
L5  1 8 1 9   S   L 3   A N D   N R S - 1
L6  7 1 2   S   L 4   A N D   X   E L S
L7  F I L E ' R E G I S T R '   E N T E R E D   A T   1 2 : 3 3 : 4 3   O N   1 2   J A N   2 0 1 0
L8  S T R   L 1
L9  F I L E ' R E G I S T R '   E N T E R E D   A T   1 2 : 4 8 : 1 2   O N   1 2   J A N   2 0 1 0
L7  2 6   S   L 6   S S S   S A M   S U B - L 3
L8  S T R   L 6
L9  3   L 6   S S S   S A M   S U B - L 3
L10 7 3   L 8   S S S   F U L   S U B - L 3
L11 4 2   S   L 1 0   A N D   N G - 1
L12 F I L E ' C A R L U S '   E N T E R E D   A T   1 2 : 5 5 : 1 5   O N   1 2   J A N   2 0 1 0
L13 1 1 7 8   S   L 1 1
L14 2 9   S   L 1 2 ( L )   T H U   R L
L15 1 1   S   L 1 3   A N D   P Y 2 0 0 4
L16 F I L E ' R E G I S T R '   E N T E R E D   A T   1 3 : 0 7 : 4 8   O N   1 2   J A N   2 0 1 0
      S T R   L 8
L17 F I L E ' R E G I S T R '   E N T E R E D   A T   1 3 : 0 8 : 2 1   O N   1 2   J A N   2 0 1 0
L18 1   S   L 1 5   S S S   F U L   S U B - L 3
L19 F I L E ' C A R L U S '   E N T E R E D   A T   1 3 : 0 8 : 4 7   O N   1 2   J A N   2 0 1 0
L17 1   S   L 1 6
L18 5 7 9 3 8   D M S C
L19 1 5 7   S   L 1 8 ( 5 A )   P H A R M A C E U T I C A L
L20 8 6   S   L 1 9   A N D   P Y - 2 0 0 3
L21 3   S   L 1 9 ( 5 A )   C A P P E R
L22 F I L E ' S T A N J U D E '   E N T E R E D   A T   1 3 : 1 7 : 4 8   O N   1 2   J A N   2 0 1 0
L23 F I L E ' R E G I S T R '   E N T E R E D   A T   1 3 : 4 1 : 3 9   O N   1 2   J A N   2 0 1 0
      S T R   L 1 5
L24 F I L E ' R E G I S T R '   E N T E R E D   A T   1 3 : 4 2 : 2 7   O N   1 2   J A N   2 0 1 0
L25 1   S   L 2 2   S S S   F U L   S U B - L 3
L26 F I L E ' C A R L U S '   E N T E R E D   A T   1 3 : 4 3 : 1 1   O N   1 2   J A N   2 0 1 0
L27 3 7   S   L 2 3
L28 6   S   L 2 3 ( L )   T H U   R L

```


\Rightarrow d que



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT EQLABEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES 15 14

```
STEREO ATTRIBUTES: NONE
L3          7168 SEA FILE=REGISTRY SSS FUL L1
L22         STR
```



VAR: GL=26/ OJ/F/H
 NCODE ATTRIBUTES
 CONNECT IS E2 FC AT 7
 DEFAULT MLEVEL IS ATOM
 DEFAULT EQLABEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC I
 NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE
 L23 15 SEA FILE=REG STRY SUB=L3 SSS FUL L22
 L24 37 SEA FILE=CAPLUS ABB=ON PLU=ON L23
 L25 6 SEA FILE=CAPLUS ABB=ON PLU=ON L24(L) THU RL

=> s i 25 and py<2004
 24054764 PY<2004
 L26 1 L25 AND PY<2004

=> d b l b a b h i t a r


L26 ANSWER 1 OF 1 CAPLUS CQPYRI GHT 2010 ACS ON STN
 AN 2003:674795 CAPLUS
 DN 140:121957
 TI Isolation of drugs active against mammalian prions using a yeast-based screening assay
 AU Bach, Stéphane; Talarek, Nicolas; Andrieu, Thibault; Vierfond, Jean-Michel; Mettrey, Yvette; Galons, Herve; Dormont, Dominique; Weijer, Laurent; Cullin, Christophe; Blondel, Marc
 CS Station Biologique, Cell Cycle Laboratory, C.N.R.S., Bretagne, 29680, Fr.
 SO Nature Biotechnology (2003), 21(8), 1075-1081
 CODEN: NABI F9; ISSN: 1087-0156
 PB Nature Publishing Group
 DT Journal
 LA English
 AB We have developed a rapid, yeast-based, two-step assay to screen for anti-prion drugs. The method allowed us to identify several compounds effective against budding yeast prions responsible for the [PSI⁺] and [URE3] phenotypes. These inhibitors include the kastelapsolines, a new class of compounds, and two previously known molecules, phenanthridine and 6-antiphenanthridine. Two potent promoters of mammalian prion clearance in vitro, quinaquine and chlorpromazine, which share structural similarities with the kastelapsolines, were also active in the assay. The compounds isolated here were also active in promoting mammalian prion clearance. These results validate the present method as an efficient high-throughput screening approach to identify new prion inhibitors and furthermore suggest that biochemical pathways controlling prion formation and/or maintenance are conserved from yeast to humans.
 IT 832-68-8 6-Phenanthridine name 851055-79-7
 851055-83-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BLO (Biological study); USES (Uses)
 (Isolation of drugs active against mammalian prions using a yeast-based screening assay)
 RN 832-68-8 CAPLUS
 CN 6-Phenanthridine name (CA INDEX NAME)



RN 851055-79-7 CAPLUS
 CN 6-Phenanthridine name, 8-chloro- (CA INDEX NAME)



RN 651055-83-3 CAPLUS
 CN 6-Phenanthridine, 8-(trifluoromethyl)- (CA INDEX NAME)



OSC G 66 THERE ARE 66 CAPLUS RECORDS THAT CITE THIS RECORD (66 CITINGS)
 RE CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>